^
    Back
    Association details:
    Biomarker:MET mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Thorac Cancer
    Title:

    Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations

    Published date:
    05/02/2022
    Excerpt:
    This single-center, retrospective cohort study included patients with advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, HER2 alterations or driver-negative, and were treated with first-line ICI therapy….Our study demonstrated patients with MET alterations had a shorter median PFS of 2.8 months, compared to those with other driver alterations and driver-negative.
    DOI:
    https://doi.org/10.1111/1759-7714.14448